Takara Bio

Takara Bio Net Debt

Delisted

The Net Debt of Takara Bio (4974.T) as of Nov 8, 2026 is -28.45 B JPY. In the previous year, Net Debt was -34.45 B JPY — a change of -17.42% (higher).

Net Debt

-28.45 BJPY

YoY

-17.42%

Last updated:

Net Debt of Takara Bio is 2025 -28.45 B JPY. Net Debt of Takara Bio was 2024 -34.45 B JPY. It decreases by -17.42% higher compared to the previous year.

The Takara Bio Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-19.54 B JPY
Jan 1, 2019
-19.03 B JPY
Jan 1, 2020
-19.15 B JPY
Jan 1, 2021
-24.85 B JPY
Jan 1, 2022
-22.59 B JPY
Jan 1, 2023
-50.88 B JPY
Jan 1, 2024
-34.45 B JPY
Jan 1, 2025
-28.45 B JPY
The Takara Bio Net Debt history
YEARNet DebtYoY
-28.45 BJPY-17.42%
-34.45 BJPY-32.29%
-50.88 BJPY+125.25%
-22.59 BJPY-9.12%
-24.85 BJPY+29.80%
-19.15 BJPY+0.59%
-19.03 BJPY-2.58%
-19.54 BJPY-34.77%
-29.95 BJPY+3.59%
-28.91 BJPY+22.27%
-23.65 BJPY-20.03%
-29.57 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Takara Bio Stock analysis

What does Takara Bio do? Takara Bio Inc is a Japanese biotechnology company that has been active in the medical and life science industry since its founding in 1967. The company is a strong player in the field of molecular biology and operates in several countries such as the USA, Europe, and Asia. Takara Bio Inc was established as an independent company in 1999, focusing exclusively on the production of molecular biology products. The company offers a wide range of products in the fields of research and diagnostics, including enzymes, PCR kits, vectors and plasmids, antibodies, proteins, and cell culture products. Takara Bio Inc is organized into two divisions: Life Science Research and Diagnostics. The Life Science Research division provides products and solutions for research and development in areas such as molecular biology, neuroscience, proteomics, and genomics. The Diagnostics division offers products and solutions for clinical diagnostics and drug development. Takara Bio Inc also specializes in the automation of molecular biology procedures and offers automated systems that can perform processes such as nucleic acid extraction, PCR, and sequencing. The company is committed to sustainability and environmental protection, adhering to strict environmental and quality standards in its production processes and implementing waste reduction and efficient resource utilization programs. Overall, Takara Bio Inc is a leading company in the field of molecular biology, offering a wide range of products and solutions for research and diagnostics, and has become a key player in the life science industry through its global expansion and ability to provide custom solutions. Takara Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Takara Bio stock

Net Debt of Takara Bio is -28.45 B JPY in 2025.

Net Debt of Takara Bio changed from -34.45 B JPY to -28.45 B JPY, representing a -17.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Takara Bio since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Takara Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Takara Bio

All Key Metrics — Takara Bio